Neoplasia-specific splice variants and methods

Details Neoplasia-specific splice variants and methods Neoplasia-specific splice variants and methods

C - Chemistry, Metallurgy

12

N

C12N 15/53 (2006.01) A61K 31/7088 (2006.01) A61K 48/00 (2006.01) C12N 1/21 (2006.01) C12N 5/10 (2006.01) C12N 15/63 (2006.01) C12P 21/02 (2006.01) C12Q 1/04 (2006.01) G01N 33/574 (2006.01)

Patent

CA 2549275

All neoplastic cells express a unique cell-surface ubiquinone (NADH) oxidase with protein disulfide-thiol isomerase with characteristic sensitivity to inhibition by capsaicin, sulfonylureas, adriamycin and certain other compounds. This neoplasia- specific protein is the translational expression production of a particular splice pattern: exon 4 is not translated to become part of the neoplasia-specific protein displayed on the surfaces of the cancer cells. Oligonucleotides which span the splice junctions of the cancer-specific mRNA can be used in RT-PCR assays, for example, having nucleotide sequences as given in SEQ ID NO:4 and in SEQ ID NO:5, which, when positive, are useful in the detection of neoplastic cells in the sample from which the mRNA was derived. Alternatively, transcriptase or real time polymerase chain reaction assays can produce amplification products of cancer-specific sizes. In addition, antisense oligonucleotides which inhibit the expression of the neoplasia-specific transcript are disclosed; these restore the normal phenotype of neoplastic cells into which they are introduced.

Affiliated with

Also associated with

Rating

Neoplasia-specific splice variants and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neoplasia-specific splice variants and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neoplasia-specific splice variants and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2027462